Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | MTOR | P42345 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523428 | 1.00 | XDH (0.67) | XDHADORA3ADORA2APDE2APIK3CA | |
| SCHEMBL28878261 | 0.84 | XDH (0.47) | XDHPDE2APIK3CAMTORPIK3CD | |
| SCHEMBL11876697 | 0.81 | XDH (0.67) | XDHADORA3ADORA2APDE4APDE4B | |
| SCHEMBL16146881 | 0.81 | ADORA3 (0.50) | XDHADORA3PDE2APIK3CAMTOR | |
| SCHEMBL8885460 | 0.81 | XDH (0.45) | XDHADORA3PDE2APIK3CAMTOR | |
| SCHEMBL6509992 | 0.81 | XDH (0.45) | XDHPDE2APIK3CAMTORPIK3CD | |
| SCHEMBL164700 | 0.80 | XDH (0.65) | XDHPDPK1GDABRAF | |
| SCHEMBL16147520 | 0.80 | XDH (0.65) | XDHADORA3ADORA2APIK3CDPDE4A | |
| SCHEMBL16147421 | 0.80 | XDH (0.65) | XDHADORA3ADORA2APDE4APDE4B | |
| SCHEMBL16146988 | 0.80 | XDH (0.65) | XDHADORA3ADORA2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1089 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250129308-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2025-04-24 | — | — | US | claimed |
| CN-119404296-A | Semiconductor processing liquid, method for processing object to be processed, and method for manufacturing electronic device | 富士胶片株式会社 | 2025-02-07 | — | — | CN | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024014224-A1 | SEMICONDUCTOR PROCESSING LIQUID, METHOD FOR PROCESSING OBJECT TO BE PROCESSED, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-01-18 | — | — | WO | claimed |
| CN-111741967-A | Nucleoside analogue, preparation method and application | 深圳市真迈生物科技有限公司 | 2020-10-02 | — | — | CN | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| CN-106967068-A | N6The photochemistry demethyl method of methyl adenine | 中国科学院化学研究所 | 2017-07-21 | — | — | CN | claimed |
| WO-2016126987-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation (US) | 2016-08-11 | — | — | WO | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| WO-2012138530-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-10-11 | — | — | WO | claimed |
| WO-2011066312-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECH HOLDING B.V. (NL) | 2011-06-03 | — | — | WO | claimed |
| US-20050239727-A1 | for use in cosmetics, drugs | SILDEHA SWISS SA (CH) | 2005-10-27 | — | — | US | claimed |
| EP-1525224-A1 | HYALURONIC ACID DERIVATIVES | Jasper Ltd. Liability Co. (US) | 2005-04-27 | — | — | EP | claimed |
| WO-2004013182-A1 | HYALURONIC ACID DERIVATIVES | JASPER LTD LIABILITY CO. (US) | 2004-02-12 | — | — | WO | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239727-A1 | for use in cosmetics, drugs | HINT1, NUDT1, NNT | XDH 87/4885ADORA3 26/4885ADORA2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.